Scientific Sessions 2025  /  TCT at AHA: Heart Team in Action: Arrhythmogenic Mitral Valve Prolapse: Predicting Risk, Protecting Patients, and Personalizing Treatment  /  Current Strategies for Medical Treatment of Arrythmogenic Mitral Valve Prolapse
Logo

American Heart Association

  37
  0

Final ID:

Current Strategies for Medical Treatment of Arrythmogenic Mitral Valve Prolapse

  • Tribouilloy, Christophe  ( Universitaire d'Amiens , Amiens , France )
  • Enriquez-sarano, Maurice  ( Minneapolis Heart Institute , Minneapolis , Minnesota , United States )
  • Michelena, Hector  ( MAYO CLINIC , Rochester , Minnesota , United States )
    • Author Disclosures:
    Christophe Tribouilloy: DO NOT have relevant financial relationships | Maurice Enriquez-Sarano: DO have relevant financial relationships ; Consultant:HighLife:Active (exists now) ; Consultant:Corcym:Active (exists now) | Hector Michelena: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

TCT at AHA: Heart Team in Action: Arrhythmogenic Mitral Valve Prolapse: Predicting Risk, Protecting Patients, and Personalizing Treatment

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
What is Mitral Annular Dysjunction? Prevalence, Definition and Prognosis

Sitges Marta, Delgado Victoria, Enriquez-sarano Maurice, Michelena Hector

Defining the Role of Ablation Therapies and ICD in Arrythmic Mitral Valve Prolapse

Miller Marc, Sabbag Avi, Delling Francesca

More abstracts from these authors:
Arrhythmogenic Mitral Valve Prolapse: Definition, Prevalence, Prognosis, and How to Predict
Sudden Death

Basso Cristina, Perazzolo Marra Martina, Enriquez-sarano Maurice, Michelena Hector

What is Mitral Annular Dysjunction? Prevalence, Definition and Prognosis

Sitges Marta, Delgado Victoria, Enriquez-sarano Maurice, Michelena Hector

You have to be authorized to contact abstract author. Please, Login
Not Available